Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Buti

Showing results (841-850 of 1,095) with videos related to

Pageof 110
Sort By:
Expert Review of Anticancer Therapy|November 5, 2021
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)Alessia Mennitto, Emma Zattarin, Massimo Di Maio, et al.
Genomics, Proteomics & Bioinformatics|May 4, 2026
Calling for Diversity: Improving Transfusion Safety Through High-Throughput Blood Group Microarray GenotypingMichael Wittig, Tim Alexander Steiert, Hesham ElAbd, et al.
Journal of Hepatology|December 19, 2015
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapyGeorge Papatheodoridis, George Dalekos, Vana Sypsa, et al.
Clinical Genitourinary Cancer|November 6, 2023
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)Alessandra Damassi, Malvina Cremante, Alessio Signori, et al.
Epilepsy Research|April 16, 2003
No evidence of GABRG2 mutations in severe myoclonic epilepsy of infancyFrancesca Madia, Elena Gennaro, Massimiliano Cecconi, et al.
Targeted Oncology|August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination TherapiesMatteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
Clinical Medicine Insights. Oncology|July 22, 2021
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)Melissa Bersanelli, Sebastiano Buti, Alessio Cortellini, et al.
European Urology|October 4, 2021
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES StudyCristina Masini, Cinzia Iotti, Ugo De Giorgi, et al.
Scientific Reports|February 6, 2024
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of deathFrancesca Minnai, Filippo Biscarini, Martina Esposito, et al.
Immunology Letters|June 21, 2024
Effect of antimetabolite regimen on cellular and humoral immune response to SARS-COV-2 vaccination in solid organ transplant recipientsManuela Capone, Anna Vanni, Lorenzo Salvati, et al.
Pageof 110

Showing results (841-850 of 1,095) with videos related to

Sort By:
Pageof 110
Expert Review of Anticancer Therapy|November 5, 2021
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)Alessia Mennitto, Emma Zattarin, Massimo Di Maio, et al.
Genomics, Proteomics & Bioinformatics|May 4, 2026
Calling for Diversity: Improving Transfusion Safety Through High-Throughput Blood Group Microarray GenotypingMichael Wittig, Tim Alexander Steiert, Hesham ElAbd, et al.
Journal of Hepatology|December 19, 2015
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapyGeorge Papatheodoridis, George Dalekos, Vana Sypsa, et al.
Clinical Genitourinary Cancer|November 6, 2023
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)Alessandra Damassi, Malvina Cremante, Alessio Signori, et al.
Epilepsy Research|April 16, 2003
No evidence of GABRG2 mutations in severe myoclonic epilepsy of infancyFrancesca Madia, Elena Gennaro, Massimiliano Cecconi, et al.
Targeted Oncology|August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination TherapiesMatteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
Clinical Medicine Insights. Oncology|July 22, 2021
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)Melissa Bersanelli, Sebastiano Buti, Alessio Cortellini, et al.
European Urology|October 4, 2021
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES StudyCristina Masini, Cinzia Iotti, Ugo De Giorgi, et al.
Scientific Reports|February 6, 2024
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of deathFrancesca Minnai, Filippo Biscarini, Martina Esposito, et al.
Immunology Letters|June 21, 2024
Effect of antimetabolite regimen on cellular and humoral immune response to SARS-COV-2 vaccination in solid organ transplant recipientsManuela Capone, Anna Vanni, Lorenzo Salvati, et al.
Pageof 110